"Why The New Dendreon Analysis Does Matter — And Why It Doesn’t"

"Last night, a researcher from Duke University presented an analysis that may help cement the case that Dendreon’s Provenge extends the lives of men with metastatic prostate cancer – if, that is, you think additional proof is needed."

Read more here

Dendreon: The Revenge of Provenge
by: David Miller

DENDREON Scores a TOUCHDOWN with PROVENGE

by: Rory Kearney

Dendreon's Prostate Vaccine Boosts Survival

Dendreon's controversial Provenge cancer vaccine may get another chance two years after the FDA rejected it. The drugmaker's stock soared on the news

Dendreon's Provenge: Government Agencies Play Hide and Seek With Facts